RS 바이러스 치료제 시장 규모 조사 : 약물 유형별, 투여 경로별, 환자 유형별, 유통 채널별, 지역별 예측(2022-2032년)

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast period 2024-2032. Respiratory syncytial virus therapeutics encompasses a variety of medical interventions aimed at preventing, managing, and treating infections caused by the respiratory syncytial virus (RSV). While RSV generally induces mild, cold-like symptoms in healthy individuals, it can escalate to severe respiratory illnesses in vulnerable populations such as infants, older adults, and those with compromised immune systems or underlying health conditions. The market is experiencing robust growth driven by the increasing prevalence of chronic respiratory conditions, rising healthcare expenditures, and technological advancements in drug discovery. However, the sector also faces significant challenges, including stringent regulatory hurdles and limited healthcare infrastructure in developing regions.

The Global Respiratory Syncytial Virus Therapeutics Market is driven by rise in chronic respiratory conditions prompting substantial investment in research and development. Additionally, higher healthcare expenditure globally has facilitated greater access to advanced therapies, boosting market growth. Technological advancements in drug discovery have also played a crucial role, leading to the development of innovative and more effective RSV therapies. However, the market's expansion is tempered by regulatory hurdles that can delay drug approval processes and the limited healthcare infrastructure in many developing countries, which hampers widespread access to these treatments.

The key regions considered for the Global Respiratory Syncytial Virus Therapeutics Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America dominated the respiratory syncytial virus therapeutics market in terms of revenue in 2023, a trend that is expected to continue due to favorable reimbursement policies and a well-established healthcare infrastructure. Furthermore, the Asia Pacific region is poised to exhibit the fastest growth over the forecast period, driven by increasing healthcare expenditure, rising awareness about RSV, and improving healthcare infrastructure.

Major market players included in this report are:

• AbbVie Inc.
• AstraZeneca PLC
• Bausch Health Companies Inc.
• Gilead Sciences
• GSK plc
• Johnson & Johnson
• Medivir AB
• Merck & Co., Inc.
• Pfizer Inc.
• Sanofi

The detailed segments and sub-segment of the market are explained below:

By Drug Type:

• Palivizumab
• Ribavirin
• Motavizumab
• Other drug types

By Route of Administration:

• Oral
• Injectable
• Intranasal
• Other route of administrations

By Patient Type:

• Adult
• Pediatrics

By Distribution Channel:

• Hospital pharmacies
• Retail pharmacies & drug stores
• Online pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market

Table of Contents

Chapter 1. Global Respiratory Syncytial Virus Therapeutics Market Executive Summary

• 1.1. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug Type
  • 1.3.2. By Route of Administration
  • 1.3.3. By Patient Type
  • 1.3.4. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Respiratory Syncytial Virus Therapeutics Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Respiratory Syncytial Virus Therapeutics Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Increasing Prevalence of Chronic Respiratory Conditions
  • 3.1.2. Rising Healthcare Expenditure
  • 3.1.3. Technological Advancements in Drug Discovery
• 3.2. Market Challenges
  • 3.2.1. Regulatory Hurdles and Approval Challenges
  • 3.2.2. Limited Healthcare Infrastructure in Developing Countries
• 3.3. Market Opportunities
  • 3.3.1. Expansion in Emerging Markets
  • 3.3.2. Innovations in Treatment Modalities

Chapter 4. Global Respiratory Syncytial Virus Therapeutics Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Drug Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Respiratory Syncytial Virus Therapeutics Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Palivizumab
  • 5.2.2. Ribavirin
  • 5.2.3. Motavizumab
  • 5.2.4. Other drug types

Chapter 6. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Route of Administration 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Respiratory Syncytial Virus Therapeutics Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Oral
  • 6.2.2. Injectable
  • 6.2.3. Intranasal
  • 6.2.4. Other route of administrations

Chapter 7. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Patient Type 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Respiratory Syncytial Virus Therapeutics Market: Patient Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Adult
  • 7.2.2. Pediatrics

Chapter 8. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Distribution Channel 2022-2032

• 8.1. Segment Dashboard
• 8.2. Global Respiratory Syncytial Virus Therapeutics Market: Distribution Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 8.2.1. Hospital pharmacies
  • 8.2.2. Retail pharmacies & drug stores
  • 8.2.3. Online pharmacies

Chapter 9. Global Respiratory Syncytial Virus Therapeutics Market Size & Forecasts by Region 2022-2032

• 9.1. North America Respiratory Syncytial Virus Therapeutics Market
  • 9.1.1. U.S. Respiratory Syncytial Virus Therapeutics Market
    • 9.1.1.1. Drug Type breakdown size & forecasts, 2022-2032
    • 9.1.1.2. Route of Administration breakdown size & forecasts, 2022-2032
    • 9.1.1.3. Patient Type breakdown size & forecasts, 2022-2032
    • 9.1.1.4. Distribution Channel breakdown size & forecasts, 2022-2032
  • 9.1.2. Canada Respiratory Syncytial Virus Therapeutics Market
• 9.2. Europe Respiratory Syncytial Virus Therapeutics Market
  • 9.2.1. U.K. Respiratory Syncytial Virus Therapeutics Market
  • 9.2.2. Germany Respiratory Syncytial Virus Therapeutics Market
  • 9.2.3. France Respiratory Syncytial Virus Therapeutics Market
  • 9.2.4. Spain Respiratory Syncytial Virus Therapeutics Market
  • 9.2.5. Italy Respiratory Syncytial Virus Therapeutics Market
  • 9.2.6. Rest of Europe Respiratory Syncytial Virus Therapeutics Market
• 9.3. Asia-Pacific Respiratory Syncytial Virus Therapeutics Market
  • 9.3.1. China Respiratory Syncytial Virus Therapeutics Market
  • 9.3.2. India Respiratory Syncytial Virus Therapeutics Market
  • 9.3.3. Japan Respiratory Syncytial Virus Therapeutics Market
  • 9.3.4. Australia Respiratory Syncytial Virus Therapeutics Market
  • 9.3.5. South Korea Respiratory Syncytial Virus Therapeutics Market
  • 9.3.6. Rest of Asia Pacific Respiratory Syncytial Virus Therapeutics Market
• 9.4. Latin America Respiratory Syncytial Virus Therapeutics Market
  • 9.4.1. Brazil Respiratory Syncytial Virus Therapeutics Market
  • 9.4.2. Mexico Respiratory Syncytial Virus Therapeutics Market
  • 9.4.3. Rest of Latin America Respiratory Syncytial Virus Therapeutics Market
• 9.5. Middle East & Africa Respiratory Syncytial Virus Therapeutics Market
  • 9.5.1. Saudi Arabia Respiratory Syncytial Virus Therapeutics Market
  • 9.5.2. South Africa Respiratory Syncytial Virus Therapeutics Market
  • 9.5.3. Rest of Middle East & Africa Respiratory Syncytial Virus Therapeutics Market

Chapter 10. Competitive Intelligence

• 10.1. Key Company SWOT Analysis
• 10.2. Top Market Strategies
• 10.3. Company Profiles
  • 10.3.1. AbbVie Inc.
    • 10.3.1.1. Key Information
    • 10.3.1.2. Overview
    • 10.3.1.3. Financial (Subject to Data Availability)
    • 10.3.1.4. Product Summary
    • 10.3.1.5. Market Strategies
  • 10.3.2. AstraZeneca PLC
  • 10.3.3. Bausch Health Companies Inc.
  • 10.3.4. Gilead Sciences
  • 10.3.5. GSK plc
  • 10.3.6. Johnson & Johnson
  • 10.3.7. Medivir AB
  • 10.3.8. Merck & Co., Inc.
  • 10.3.9. Pfizer Inc.
  • 10.3.10. Sanofi

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes